Cas:72010-19-6 2-propyl-3-pentenoic acid manufacturer & supplier

Chemical Name:2-propyl-3-pentenoic acid

CAS.NO:72010-19-6

Synonyms:3-Pentenoic acid,2-propyl;3-ENEVALPROIC ACID

Molecular Formula:C₈H₁₄O₂

Molecular Weight:142.19600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:236.6ºC at 760 mmHg

Density:0.953g/cm3

Index of Refraction:1.457

PSA:37.30000

Exact Mass:142.09900

LogP:2.06340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Pentenoic acid,2-propyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-ENEVALPROIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Pentenoic acid,2-propyl Use and application,3-ENEVALPROIC ACID technical grade,usp/ep/jp grade.

Related News: Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 2-propyl-3-pentenoic acid manufacturer AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 2-propyl-3-pentenoic acid supplier On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday. 2-propyl-3-pentenoic acid vendor AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 2-propyl-3-pentenoic acid factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.